Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product
4-1-2011 Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agre... read more
Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™
8-7-2010 Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (... read more
Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
28-4-2010 Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplant... read more
Kiadis Pharma Press Releases
Kiadis Pharma Press Releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.
More News
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium
- Kiadis Pharma presents at the EBMT in Göteborg
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
- Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board
- Kiadis Pharma receives two orphan drug designations for Reviroc™ from the FDA
- Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™
- Kiadis Pharma announces continued collaboration with Professor Velardi on its lead product ATIR™
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at 50th ASH Annual Meeting and Exposition by NIH investigators
- EMEA grants Kiadis Pharma lead product ATIR™ orphan drug designation
- Kiadis Pharma presents at the BIO 2008 conference in San Diego, USA
- Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
- Kiadis Pharma presents at the BioEquity Europe 2008 conference in Amsterdam
- Kiadis Pharma receives Orphan Drug Designation for Rhitol™ from the FDA
- Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ presented by NIH investigators
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™
- Kiadis Pharma presents at the 10th annual BIO CEO & Investor conference
